- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
Case T-839/14: Action brought on 22 December 2014 — Alnapharm v OHIM — Novartis (Alrexil)
ECLI:EU:UNKNOWN:62014TN0839
62014TN0839
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
23.2.2015
EN
Official Journal of the European Union
C 65/49
(Case T-839/14)
(2015/C 065/66)
Language in which the application was lodged: English
Parties
Applicant: Alnapharm GmbH & Co. KG (Hamburg, Germany) (represented by: H. Heldt, lawyer)
Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (OHIM)
Other party to the proceedings before the Board of Appeal: Novartis AG (Basel, Switzerland)
Details of the proceedings before OHIM
Applicant: The other party to the proceedings before the Board of Appeal
Trade mark at issue: Community word mark ‘Alrexil’ — Application for registration No 10 306 249
Procedure before OHIM: Opposition proceedings
Contested decision: Decision of the Fourth Board of Appeal of OHIM of 23 October 2014 in Case R 1723/2013-4
Form of order sought
The applicant claims that the Court should:
—annul the contested decision and refer the case back to the Board of Appeal of OHIM;
—order OHIM to pay the costs.
Plea in law
—Infringement of Article 8(1)(b) of Regulation No 207/2009.